Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajanta Pharma has submitted to BSE and NSE copies of its Q1 FY26 (quarter ended 30 June 2025) financial results that were published in the Mumbai editions of Business Standard and Navakal on 29 July 2025, as required under SEBI Listing Regulations. The Board had approved these results on 28 July 2025, and they were also subject to a limited review by the statutory auditors. Note: the detailed financial numbers visible in the filing appear to belong to Vidhi Specialty Food Ingredients Limited rather than Ajanta Pharma, suggesting a newspaper clipping/data mismatch in the document. Key visible figures (attributed to Vidhi, not Ajanta) include total income of Rs 8,839.62 lakh, net profit after tax of Rs 1,272.05 lakh, EPS of Rs 2.55, and a 1st interim dividend of Rs 1.50 per share (150%) declared for FY26.
This is a routine regulatory compliance filing with no direct impact on the stock price. Investors should refer to Ajanta Pharma's separate Q1 FY26 results announcement for actual company-specific numbers, as the figures visible in the submitted newspaper clipping appear to belong to a different company.